Home Compare AMGN vs SAN.PA
Stock Comparison · Industry comparison · Drug Manufacturers - General

Amgen vs Sanofi: Which Stock Looks Stronger in 2026?

Amgen holds the cleaner structural position, with profitability as the main driver and growth adding further support. Sanofi still has the edge on stability, which keeps the comparison from looking entirely one-sided. The market setup broadly confirms the structural lead — Amgen holds the more constructive position. That puts structure and market broadly in agreement — Amgen's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in profitability, but growth adds another real layer to the result. The overall score gap is 17 points in favour of Amgen Inc..

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. AMGN and SAN.PA share the same industry classification.

For a similarity-based comparison, see how Amgen and Sanofi each position within their functional peer groups in AssetNext.

Peer-Relative Score
AMGN
Amgen Inc.
63
Peer-Score
Signal qualityHigh
vs
SAN.PA
Sanofi
46
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: AMGN vs SAN.PA Profitability 50 16 Stability 57 67 Valuation 73 59 Growth 75 51 AMGN SAN.PA
Gap Ranking
#1 Profitability +34
#2 Growth +24
#3 Valuation +14
#4 Stability +10
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AMGN and SAN.PA Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AMGNSAN.PA Relative valuation Structural strength

Amgen Inc. looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
On profitability, Amgen Inc. is positioned higher in the group, while Sanofi is closer to the middle.
Growth
Both look solid on growth, though Amgen Inc. still holds the stronger peer position.
Profitability — Dominant Gap
AMGN
50
SAN.PA
16
Gap+34in favour of AMGN

The profitability lead is mainly driven by a 16.3-point operating margin advantage.

What else supports the lead

Earnings growth is one contributing factor within the growth lead.

What this means for the comparison

Profitability is the clearest driver of the lead, with growth adding further support — though stability still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the AMGN vs SAN.PA comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-and-growth comparisons

Explore how AMGN and SAN.PA each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.